Also listed on Sarcode Bioscience Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Collateral for a security interest recorded Dec 23, 2025 (JPMorgan Chase Bank, N.A.).
Term ends no later than Apr 15, 2029 · Medium confidence
20-year base term ends Apr 15, 2029
In force on USPTO's status record and by its fee record. A terminal disclaimer on file may shorten this term, possibly to a date already past; its reference document is unresolved, so the date above is an upper bound and no earlier date is guessed.
Held by Bausch + Lomb Ireland Limited
Filed Nov 4, 2011 as application 13/289,172 · Granted Feb 5, 2013
Base term, 20 years from filing
Today
2009
2029
Clock starts
Apr 15, 2009
Apr 15, 2009
Ends no later than
Apr 15, 2029
Apr 15, 2029
Granted
Feb 5, 2013
Feb 5, 2013
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
8
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. All three maintenance fees are recorded paid; no more fees are due. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Apr 15, 2009, when application 12/386,361, the earliest non-provisional in its chain, was filed (this one was filed Nov 4, 2011) | Apr 15, 2029 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | no later than Apr 15, 2029 | Medium confidence |
This family
| US 8,080,562 | In force Jul 2030 | Jul 2030 |
| US 8,367,701 | this patent no later than Apr 2029 | no later than Apr 2029 |
| US 8,871,935 | In force Apr 2029 | Apr 2029 |
| US 9,447,077 | In force Apr 2029 | Apr 2029 |
| US 11,028,077 | In force Apr 2029 | Apr 2029 |
| Application 17/323,693 | Abandoned not computed | not computed |
| Application 18/337,565 | Abandoned not computed | not computed |
| Application 18/439,671 | Pending not computed | not computed |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Nov 30, 2011 Reel 27306, frame 165 | Burnier, John; Gadek, Thomas; Naud, Frederic | Sarcode Bioscience Inc. | Assignment of Assignor's Interest |
| Nov 15, 2012 Reel 29303, frame 381 | Sarcode Corporation | Sarcode Bioscience Inc. | Change of Name |
| Feb 8, 2013 Reel 29778, frame 888 | Sarcode Bioscience Inc. | Silicon Valley Bank | Security Agreement |
| Apr 25, 2013 Reel 30295, frame 28 | Silicon Valley Bank | Sarcode Bioscience Inc. | Release of Security Interest |
| Apr 13, 2017 Reel 42245, frame 456 | Burnier, John; Gadek, Thomas; Naud, Frederic | Sarcode Corporation | Corrective Assignment to Correct the Assignee Name and Address Previously Recorded at Reel: 027306 Frame: 0165. Assignor(S) Hereby Confirms the Assignment . |
| Oct 31, 2019 Reel 50900, frame 268 | Sarcode Bioscience Inc. | Novartis AG | Assignment of Assignor's Interest |
| Oct 22, 2020 Reel 54134, frame 708 | Novartis AG | Novartis Pharmaceuticals Corporation | Assignment of Assignor's Interest |
| Dec 6, 2023 Reel 65789, frame 853 | Novartis Pharmaceuticals Corporation | Bausch + Lomb Ireland Limited | Assignment of Assignor's Interest |
| Dec 23, 2025 Reel 74050, frame 573 | Bausch + Lomb Ireland Limited | JPMorgan Chase Bank, N.A., as Collateral Agent | Intellectual Property Security Agreement |
| Dec 23, 2025 Reel 74050, frame 709 | Bausch + Lomb Ireland Limited | Citibank, N.A., as Notes Collateral Agent | Intellectual Property Security Agreement |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Apr 2029
Term ends no later than Apr 15, 2029. No further fees fall due before then
Note
A terminal disclaimer is on file and its reference is not resolved. No cap is applied and none is guessed
Open question
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than Apr 15, 2029. We will not guess the cap.
Citations
49
later US patents cite this one
That is top 25% of utility patents granted in 2013 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
This computed term ends no later than the date shown; an unresolved terminal disclaimer may end it earlier. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.